vs
Side-by-side financial comparison of Baxter International (BAX) and CACI INTERNATIONAL INC (CACI). Click either name above to swap in a different company.
Baxter International is the larger business by last-quarter revenue ($3.0B vs $2.2B, roughly 1.3× CACI INTERNATIONAL INC). CACI INTERNATIONAL INC runs the higher net margin — 5.6% vs -37.9%, a 43.5% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 5.7%). Over the past eight quarters, CACI INTERNATIONAL INC's revenue compounded faster (7.0% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
CACI International Inc is a U.S.-headquartered multinational professional services and information technology firm. It delivers custom technology solutions, cybersecurity services, data analytics, and mission-critical operational support to government defense, intelligence, civilian agencies, and select private sector clients.
BAX vs CACI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $2.2B |
| Net Profit | $-1.1B | $123.9M |
| Gross Margin | 19.4% | — |
| Operating Margin | -24.5% | 9.3% |
| Net Margin | -37.9% | 5.6% |
| Revenue YoY | 458.0% | 5.7% |
| Net Profit YoY | -120.3% | 12.7% |
| EPS (diluted) | $-2.21 | $5.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | $2.2B | ||
| Q3 25 | $2.8B | $2.3B | ||
| Q2 25 | $2.8B | $2.3B | ||
| Q1 25 | $2.6B | $2.2B | ||
| Q4 24 | $533.0M | $2.1B | ||
| Q3 24 | $2.7B | $2.1B | ||
| Q2 24 | $3.8B | $2.0B | ||
| Q1 24 | $3.6B | $1.9B |
| Q4 25 | $-1.1B | $123.9M | ||
| Q3 25 | $-46.0M | $124.8M | ||
| Q2 25 | $91.0M | $157.9M | ||
| Q1 25 | $126.0M | $111.9M | ||
| Q4 24 | $-512.0M | $109.9M | ||
| Q3 24 | $140.0M | $120.2M | ||
| Q2 24 | $-314.0M | $134.7M | ||
| Q1 24 | $37.0M | $115.3M |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | — | ||
| Q2 25 | 35.3% | — | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 37.5% | — | ||
| Q1 24 | 38.6% | — |
| Q4 25 | -24.5% | 9.3% | ||
| Q3 25 | 6.1% | 9.3% | ||
| Q2 25 | 6.8% | 9.0% | ||
| Q1 25 | 2.2% | 9.1% | ||
| Q4 24 | -25.5% | 8.6% | ||
| Q3 24 | 5.7% | 8.7% | ||
| Q2 24 | -5.0% | 9.7% | ||
| Q1 24 | 5.2% | 9.4% |
| Q4 25 | -37.9% | 5.6% | ||
| Q3 25 | -1.6% | 5.5% | ||
| Q2 25 | 3.2% | 6.9% | ||
| Q1 25 | 4.8% | 5.2% | ||
| Q4 24 | -96.1% | 5.2% | ||
| Q3 24 | 5.2% | 5.8% | ||
| Q2 24 | -8.2% | 6.6% | ||
| Q1 24 | 1.0% | 6.0% |
| Q4 25 | $-2.21 | $5.59 | ||
| Q3 25 | $-0.09 | $5.63 | ||
| Q2 25 | $0.18 | $7.11 | ||
| Q1 25 | $0.25 | $5.00 | ||
| Q4 24 | $-0.99 | $4.88 | ||
| Q3 24 | $0.27 | $5.33 | ||
| Q2 24 | $-0.62 | $5.97 | ||
| Q1 24 | $0.07 | $5.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $423.0M |
| Total DebtLower is stronger | $9.5B | $3.0B |
| Stockholders' EquityBook value | $6.1B | $4.1B |
| Total Assets | $20.1B | $8.9B |
| Debt / EquityLower = less leverage | 1.55× | 0.72× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | $423.0M | ||
| Q3 25 | $1.7B | $133.0M | ||
| Q2 25 | $1.7B | $106.2M | ||
| Q1 25 | $2.3B | $223.9M | ||
| Q4 24 | $1.8B | $175.7M | ||
| Q3 24 | $1.4B | $440.7M | ||
| Q2 24 | $2.1B | $134.0M | ||
| Q1 24 | $3.0B | $159.2M |
| Q4 25 | $9.5B | $3.0B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $3.1B | ||
| Q4 24 | $10.4B | $3.1B | ||
| Q3 24 | $10.4B | $1.8B | ||
| Q2 24 | $10.4B | $1.5B | ||
| Q1 24 | $11.1B | $1.7B |
| Q4 25 | $6.1B | $4.1B | ||
| Q3 25 | $7.2B | $4.0B | ||
| Q2 25 | $7.3B | $3.9B | ||
| Q1 25 | $7.1B | $3.7B | ||
| Q4 24 | $7.0B | $3.7B | ||
| Q3 24 | $7.9B | $3.7B | ||
| Q2 24 | $7.6B | $3.5B | ||
| Q1 24 | $8.2B | $3.4B |
| Q4 25 | $20.1B | $8.9B | ||
| Q3 25 | $21.1B | $8.7B | ||
| Q2 25 | $21.0B | $8.6B | ||
| Q1 25 | $21.3B | $8.6B | ||
| Q4 24 | $25.8B | $8.5B | ||
| Q3 24 | $26.7B | $7.2B | ||
| Q2 24 | $26.3B | $6.8B | ||
| Q1 24 | $27.8B | $6.8B |
| Q4 25 | 1.55× | 0.72× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | 1.49× | 0.82× | ||
| Q3 24 | 1.33× | 0.50× | ||
| Q2 24 | 1.37× | 0.44× | ||
| Q1 24 | 1.36× | 0.50× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $154.2M |
| Free Cash FlowOCF − Capex | — | $138.2M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | 1.24× |
| TTM Free Cash FlowTrailing 4 quarters | — | $634.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | $154.2M | ||
| Q3 25 | $237.0M | $171.1M | ||
| Q2 25 | $217.0M | $156.0M | ||
| Q1 25 | $-193.0M | $230.3M | ||
| Q4 24 | $488.0M | $126.0M | ||
| Q3 24 | $253.0M | $34.7M | ||
| Q2 24 | $115.0M | $157.2M | ||
| Q1 24 | $163.0M | $198.3M |
| Q4 25 | — | $138.2M | ||
| Q3 25 | — | $154.1M | ||
| Q2 25 | — | $128.0M | ||
| Q1 25 | — | $214.1M | ||
| Q4 24 | — | $116.1M | ||
| Q3 24 | — | $23.2M | ||
| Q2 24 | — | $134.6M | ||
| Q1 24 | — | $186.6M |
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | — | 5.6% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 9.6% |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | 2.38× | 0.99× | ||
| Q1 25 | -1.53× | 2.06× | ||
| Q4 24 | — | 1.15× | ||
| Q3 24 | 1.81× | 0.29× | ||
| Q2 24 | — | 1.17× | ||
| Q1 24 | 4.41× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
CACI
| Service Other | $876.3M | 39% |
| Intelligence Community | $539.0M | 24% |
| Federal Civilian Agencies | $438.6M | 20% |
| Subcontractor | $202.5M | 9% |
| Other | $148.5M | 7% |
| Commercial And Other | $15.2M | 1% |
